| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Oxaliplatin (L-OHP) has been developed as a third-generation platinum compound for the treatment of gastroenterological cancer in chemotherapy, including FOLFOX, CapOX, SOX, and FOLFIRINOX. Undesirable side effects, such as emesis, diarrhea, nausea, vomiting, muscle pain, joint pain, and peripheral neuropathy, cause discontinuation of therapy, indicating inadequate treatment. L-OHP-induced neuropathy is predominant reason for extension of the withdrawal period, and termination of therapy. Two different strategies have been advocated to prevent L-OHP-induced neuropathy: a Stop-and -Go approach and the concurrent use of neuromodulatory agents, including antidepressants, antiepileptics, or calcium and magnesium infusions. However, neither strategy is sufficiently effective. In order to prevent serious side effects and safely complete the chemotherapy regimen, this study investigated the pharmacokinetic and toxicodynamic properties of L-OHP in colorectal cancer model rats.
|
